News >

FDA Approves Pembrolizumab for Microsatellite Instability-High and Mismatch Repair Deficient Cancers

Jason M. Broderick @jasoncology
Published: Tuesday, May 23, 2017

Dr. Richard Pazdur

Richard Pazdur, MD

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, as well as for patients with MSI-H or dMMR colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x